Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
- Conditions
- HIV InfectionsHIV-hepatitis Co-infection
- Registration Number
- NCT00662194
- Lead Sponsor
- Bayside Health
- Brief Summary
Data from this study will provide the first information how the innate immune system may be altered in HIV-HCV and HIV-HBV co-infected individuals, and describe Toll-like receptor changes with HIV co-infection therapy.
- Detailed Description
It has been demonstrated that Toll-like receptors (TLR) are involved in viral hepatitis - hepatitis B (HBV), hepatitis C (HCV) - and HIV in the setting of mono-infection. However the role of innate immunity in the pathogenesis of HIV-hepatitis co-infection in both natural and therapy-associated viral clearance remains unclear. The data from this study may reveal patterns which could predict how and when patients spontaneously, and with therapy, resolve HBV or HCV in the setting of co-infection.
The aim of the study is to evaluate the activity of innate immunity in different subsets of HIV-infected populations co-infected with chronic hepatitis B and/or C. Our hypothesis is that innate immunity is altered in HIV and hepatitis co-infection and that this differs from both hepatitis and HIV mono-infection.
The study is a cross-sectional and longitudinal pilot study of individuals infected with HIV and either HBV or HCV.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
- HIV and either HBV or HCV co-infection
- 18 years and older
- able to give informed consent
- HIV-HBV-HCV triple infection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method TLR change with HIV co-infection therapy 6 months
- Secondary Outcome Measures
Name Time Method TLR change patterns on spontaneously and on treatment resolved HBV or HCV in the co-infected setting 6 months
Trial Locations
- Locations (1)
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia